AIV Logo AIV Assistant

Loading...

 Logo Gamida Cell Ltd. - GMDA 0.03 USD

EPS
-0.82
P/B
10.90
ROE
-1103.79
Beta
1.03
Target Price
4.00 USD

0.033 USD

0.033 USD

Daily: +0.00%
Key Metrics

EPS: -0.82

Book Value: 0.00

Price to Book: 10.90

Debt/Equity: 22308.38

% Insiders: 11.578%

Estimates

Forward P/E: -0.06

Forward EPS: -0.56

Target Mean Price: 4.00

 Logo About Gamida Cell Ltd. - (GMDA)

Country: Israel

Sector: Health Care

Website: http://www.gamida-cell.com

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

Exchange Ticker
NGM (Sweden) GMDA

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion